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Summary
Background Sickle-cell disease increases the risk of malnutrition. Low arginine and nitric oxide bioavailability are 
implicated in morbidity related to sickle-cell disease. Simple interventions are required, especially in low-income 
settings. We aimed to test the hypotheses that: (1) supplementary arginine, citrulline, and daily chloroquine increase 
bioavailable arginine and flow-mediated dilatation (FMD; maximal diameter change; FMDmax%), a measure of nitric 
oxide-dependent endothelial function; and (2) protein energy supplementation in the form of ready-to-use 
supplementary food (RUSF) improves the height-for-age and body-mass index-for-age Z-scores in children with 
sickle-cell disease.
Methods We performed a double-blind, random order crossover trial with two 4-month intervention periods (each 
followed by 4-month washout periods) in Muhimbili National Hospital in Dar-es-Salaam, Tanzania. We enrolled 
119 children from the Muhimbili Sickle Cohort who were aged 8–12 years, naive to hydroxyurea, and had documented 
HbSS phenotype. Two formulations of RUSF (providing 500 kcal/day) were tested: basic (RUSF-b), with which 
children also received weekly chloroquine (150 mg or 225 mg chloroquine base, dependent on bodyweight); and 
vascular (RUSF-v), which was fortified with arginine and citrulline (designed to achieve mean intakes of 0·2 g/kg per 
day of arginine and 0·1 g/kg per day of citrulline), and with which children received daily chloroquine (maximum 
3 mg chloroquine base/kg per day). Children were randomly allocated to receive either RUSF-b first or RUSF-v first 
and, after a washout period, were then given the other treatment. The primary outcomes in comparing the two RUSF 
formulations were mean plasma arginine, arginine to ornithine ratio, and arginine to asymmetric dimethylarginine 
ratio, and mean FMDmax%. The primary outcomes of the combined effect of both RUSF interventions were mean 
height-for-age Z-score and body-mass index-for-age Z-score. Analyses were done on the eligible intention-to-treat 
population. This trial is registered with ClinicalTrials.gov, number NCT01718054; and with ISRCTN74331412.
Findings Between Aug 9, 2012, and Feb 26, 2014, 145 children were randomised (71 children to RUSF-v first and 
74 children to RUSF-b first) and 119 children were treated, of whom 114 children yielded complete data for all reported 
endpoints. The ratio of arginine to ornithine (mean of individual differences –8·67%, 95% CI –19·55 to 2·20; p=0·12) 
and the mean FMDmax% (1·00, –0·47 to 2·47; p=0·18) did not significantly differ between the RUSF-b and RUSF-v 
treatments. However, the arginine to asymmetric dimethylarginine ratio was significantly increased by RUSF-v 
compared with RUSF-b (56·26%, 31·13 to 81·38; p<0·0001). In planned analyses that used mixed effects models to 
estimate the effect of each intervention compared with the participants at baseline or during washout periods, the 
arginine to asymmetric dimethylarginine ratio increased following both RUSF-v treatment (86%; p<0·0001) and 
RUSF-b treatment (40%; p<0·0001). However, FMDmax% was higher after treatment with RUSF-v (0·92; p<0·0001) 
but not RUSF-b (0·39; p=0·22). Following either intervention (RUSF-b and RUSF-v, pooled) body-mass index-for-age 
Z-score (0·091; p=0·001) and height-for-age Z-score (0·013; p=0·081) increased compared with baseline and washout 
timepoints. In 83 participants in the treated population, there were 71 adverse events during the intervention, of 
which 21 (30%) were serious, and 81 adverse events during the washout periods, of which 26 (32%) were serious 
(p=0·31), including one patient who died in the second washout period. 
Interpretation RUSF providing 500 kcal/day results in small weight gains in children with sickle-cell disease. 
However, even without arginine and citrulline fortification, RUSF seems to ameliorate arginine dysregulation and 
might improve endothelial function. Long-term studies are required to assess whether these physiological effects 
translate to improved clinical outcomes and better growth and development in patients with sickle-cell disease.
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Introduction
About 6 million people live with sickle-cell disease in 
Africa.1 As survival increases, the number of people 
requiring chronic care will increase while the costs and 
complexity of follow-up interventions limit implemen-
tation; these include prophylactic blood transfusions and 
hydroxyurea therapy to the maximum tolerated dose.
Reduced growth is frequently observed in children 
with sickle-cell disease.2,3 Energy and nutrient supplies 
are reduced in sickle-cell disease, resulting from 
decreased dietary intake, increased metabolic rate, 
increased nutrient degradation, and impaired metabolic 
pathways.4,5 The possibility that the complications of 
sickle-cell disease might be ameliorated by appropriate 
dietary supplementation of protein, energy, and micro-
nutrients has received little attention.
Vasculopathy, an important cause of morbidity and 
mortality in sickle-cell disease,6 is associated with 
endothelial dysfunction. This dysfunction includes 
increased endothelial cell activation and adhesion, 
abnormal tone, responsiveness, and vessel architecture,7 
which can be disrupted by intravascular haemolysis, 
increased oxidative stress, and decreased nitric oxide 
bioavailability. Arginase is released from ruptured 
erythrocytes, platelets, and the liver.8 High concentrations 
of arginase reduce plasma arginine,9 the sole substrate of 
endothelial nitric oxide synthase, thereby decreasing 
nitric oxide production. Ornithine is the degradation 
product of arginase and is a competitive inhibitor of 
arginine uptake by endo thelial cells, thus the arginine to 
ornithine ratio could be crucial for endothelial nitric 
oxide synthase activity. In patients with sickle-cell 
disease, low plasma arginine is common,10,11 and is 
further decreased during vaso-occlusive episodes and 
acute chest syndrome.12 Low arginine to ornithine ratios 
and high asymmetric dimethylated arginine (ADMA), an 
endo genous inhibitor of endothelial nitric oxide synthase, 
are associated with increased pulmonary artery pressure 
and death.9,13,14 Reduced nitric oxide bioavailability is 
implicated in the pathophysiology of several disorders 
involving endothelial function, including sickle-cell 
disease, hypertension, and chronic kidney disease.15–17 
Improving arginine concentrations might improve 
outcomes in these disorders. In adults with sickle-cell 
disease, oral arginine reduced pulmonary artery pressure 
by 15·2%,18 and children with acute pain who were 
randomly allocated to receive intravenous arginine 
required less analgesia than did children receiving 
placebo.19 The effects of longer-term supplementation of 
arginine on endothelial function in sickle-cell disease or 
on clinically important endpoints such as pain is 
unknown.
Flow-mediated dilatation (FMD) is a non-invasive 
ultrasound-based technique for assessing endothelial 
function by measuring the vasodilator response of the 
brachial artery to increased blood flow, which is 
dependent on local nitric oxide bioavailability and is a 
validated marker of vascular endothelial function and 
risk of arterial disease development.20 Alterations to the 
vasodilator responses enable the exploration of mech-
anisms involved in the initiation and progression of 
pre-clinical vascular disease in children21 and the 
evaluation of interventions in clinical trials.22 Endothelial 
function is abnormal in adults23,24 and children25 with 
sickle-cell disease, and can improve after blood trans-
fusion.26
We investigated whether arginine and citrulline 
fortification of a ready-to-use-supplementary food (RUSF), 
accompanied by an anti-inflammatory dose of chloroquine 
(a potential competitive inhibitor of arginase),27 increases 
Research in context
Evidence before this study
Before completion of the protocol, we searched ClinicalTrials.
gov and the ISRCTN.gov clinical trials registries for unpublished 
randomised trials using the search term “sickle” within 
conditions; “arginine” or “citrulline” or “chloroquine” within 
interventions; and “energy” or “protein” or “food” or 
“supplement” combined with “sickle” within conditions. Similar 
searches were done in PubMed and were restricted to papers in 
English that were published before September, 2011. 
No previous randomised trials of a protein energy intervention 
in humans with sickle-cell disease have ever been registered or 
reported.
Added value of this study
To our knowledge, this trial is one of the first reported 
intervention trials for people living with sickle-cell disease in 
Africa, where most affected people reside. RUSF with arginine 
and citrulline fortification and daily chloroquine did not 
significantly increase plasma global arginine bioavailability ratio 
or flow-mediated dilatation (as a measure of endothelial 
function) compared with unfortified RUSF and weekly 
chloroquine. However, in planned analyses of the effects of each 
intervention and both combined, we observed significantly 
improved global arginine bioavailability ratio, arginine to 
asymmetric dimethylated arginine ratios, improved measures of 
endothelial function, and small improvements in height-for-age 
and body-mass index-for-age Z-scores after both interventions 
compared with baseline and washout measurements. No effect 
on inflammation was observed, suggesting a weak effect of the 
daily anti-inflammatory dose of chloroquine.
Implications of all the available evidence
Protein energy malnutrition, along with associated micronutrient 
deficiencies, might underlie some of the metabolic and 
physiological irregularities observed in sickle-cell disease, 
including arginine dysregulation and reduced endothelial 
function. Treatment and prevention of protein-energy 
malnutrition warrants much higher clinical priority.
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bioavailable arginine and improves nitric oxide-mediated 
endothelial function, and tested whether RUSF improves 
nutritional status. The trial was designed to simultaneously 
address two separate questions: (1) the effect of arginine-
fortified and citrulline-fortified RUSF on bioavailable 
arginine concentrations and endothelial function; and (2) 
the combined effect of RUSF formulation with and 
without these supplements on nutritional status.
Methods
Study design and participants
We did a double-blind, random order crossover trial of 
two RUSF formulations in children with sickle-cell 
disease: a basic formulation with weekly chloroquine 
(RUSF-b) or a vascular formulation (RUSF-v), which was 
fortified with arginine and citrulline and daily 
chloroquine. The trial was done in Muhimbili National 
Hospital in Dar es Salaam, Tanzania.
Eligible participants were children previously enrolled 
in the Muhimbili Sickle Cohort, for which the methods 
of recruitment and survival have been previously 
described.1 Children were enrolled between Aug 9, 2012, 
and Dec 3, 2012. All participants had been prescribed 
folate supplementation and advised to use insecticide-
treated bednets. Chloroquine was not available before the 
start of this trial, since it was banned for treatment of 
malaria, and no other malaria prophylaxis was being 
implemented at the time of this trial.
The children lived in urban Dar-es-Salaam, had docu-
mented HbSS (determined by high-performance liquid 
chromatography [Variant II; Bio-Rad Laboratories, 
Hercules, CA, USA]), were aged 8–11 years at enrolment, 
and were naive to hydroxyurea therapy. Exclusion criteria 
and recruitment procedures are detailed in the appendix 
(pp 1–2). The key exclusion criteria were being over-
weight, low visual acuity, substantial renal or hepatic 
dysfunction (as indicated by abnormal clinical chemistry), 
and other serious comorbidities (such as receiving drugs 
known to interact with chloroquine).
The study was approved in Tanzania (National Institute 
of Medical Research and Muhimbili University of Health 
& Allied Sciences) and the UK (London School of 
Hygiene & Tropical Medicine). Parents or guardians 
provided written informed consent and children gave 
documented assent. The trial protocol is available online. 
Randomisation and masking
Patients were randomly assigned to receive either 
RUSF-b first, followed by RUSF-v, or RUSF-v first, 
followed by RUSF-b. The RUSF manufacturer generated 
the study participant identification codes in advance. 
Eligible participants were allocated a study identification 
code in the order that they were enrolled for laboratory 
screening for presence of abnormal liver or kidney 
function by the clinical research assistants in the study 
clinic. Participants were given an identification code and 
randomly assigned one of four treatment codes for each 
of the two treatment periods (indicated by different 
shapes printed on each, otherwise identical, RUSF 
packet) in blocks of 12 by use of the random function in 
Microsoft Excel. The same allocation code was used for 
the chloroquine, which was provided as a Monday to 
Saturday dosing bottle and Sunday dosing bottle that 
contained either base syrup alone or the appropriate 
concentration of chloroquine, as per the allocation code 
for each intervention period (appendix p 3). The list of 
identification numbers was linked to one of the four 
shape codes in another file accessed only by the field 
workers who delivered the intervention, but who were 
not involved in the outcome assessments at the clinic 
visits. The allocation code was known only to the RUSF 
manufacturer, the data safety monitoring board, and the 
study pharmacist. Investigators, clinical research assis-
tants, field workers, care providers, and participants were 
blinded to the allocation code until final data analysis.
Procedures
The randomly allocated interventions were administered 
for 4 months, followed by a 4-month washout; the other 
intervention was then administered for 4 months, 
followed by a second 4-month washout (appendix p 1). 
We used this study design: (1) as a standard analysis of 
the two treatments, allocated in a random order, to 
compare RUSF-v with RUSF-b treatment; and (2) to 
assess changes in endpoints after each treatment 
compared with baseline and washout timepoints and, 
where no evidence of differential effects were observed 
or expected, to calculate the average effect of both 
treatments combined. This approach effectively treats 
the study as a non-randomised, before-and-after inter-
vention study within the same participants.
Both interventions consisted of twice-daily admini-
stration of RUSF, which was manufactured by Nutriset, 
(Malaunay, France), and was based on their supple-
mentary PlumpyNut, which is used in the treatment of 
moderate malnutrition.28 This RUSF was compre-
hensively fortified with vitamins and minerals at 
approximately the recommended daily allowance (except 
for folate [1 mg/day] and iron [no fortification]) and 
provided 500 kcal/day (appendix p 3). RUSF-v was also 
fortified with 5·0 g (for participants with bodyweights of 
<25 kg) or 7·5 g (for participants with bodyweights of 
≥25 kg) of L-arginine ketoglutarate and 2·5 g 
(bodyweights <25 kg) or 3·75 g (bodyweights ≥25 kg) of 
L-citrulline, to achieve mean intakes of 0·2 g/kg per day 
of L-arginine and 0·1 g/kg per day of L-citrulline and 
maximum intakes of 0·33 g/kg per day of L-arginine and 
of 0·165 g/kg per day of L-citrulline (appendix p 4). 
RUSF-v was administered with daily chloroquine syrup 
(Wallace Manufacturing Chemicals, Abingdon, UK) at 
either 50 mg (bodyweights <25 kg) or 75 mg (bodyweights 
≥25 kg) chloroquine base to achieve a maximum dose of 
3 mg chloroquine base/kg per day. RUSF-b was 
administered with weekly chloroquine at 150 mg 
See Online for appendix
For the trial protocol see 
http://doi.org/10.17037/
PUBS.04646119
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(bodyweights <25 kg) or 225 mg (bodyweights ≥25 kg) 
chloroquine base per week. The RUSF packs and 
chloroquine were delivered fortnightly by study field 
workers who collected used chloroquine bottles and 
unused RUSF packs and assessed compliance 
(appendix p 4).
Participants attended the study clinic at enrolment 
(baseline) and at the end of each intervention and 
washout period (clinic visits 0–4; where baseline=0, 
end of intervention 1=1, end of washout 1=2, end of 
intervention 2=3, and end of washout 2=4). During 
these visits, a brief clinical examination was done and, if 
the participant was determined to be clinically well, the 
outcome measures were assessed. Participants who 
were found to be unwell were booked for another study 
clinic visit the following week. Participants continued to 
receive the intervention or remain in washout until they 
were judged to be clinically well at a clinic visit.
At each clinic visit, a 5 mL blood sample was collected. 
Aminoacid concentrations were measured by ion-
exchange elution (Biochrom-30; Biochrom, Cambridge, 
UK) of frozen lithium heparin plasma, which was frozen 
within 2 h of collection at clinic visits 0, 1, and 3 
(appendix p 5). Complete blood count and haemoglobin 
concentrations were measured at all clinic visits from 
ethylenediaminetetraacetic acid–whole blood (Sysmex 
XT2000i; Sysmex, Kobe, Japan; or ABX Pentra 60; Horiba, 
Kyoto, Japan). The concentrations of lactate dehydrogenase, 
total and direct bilirubin, aspartate transaminase, alkaline 
phosphatase, and creatinine were measured from fresh 
serum, taken at clinic visits 0–3, by use of an automated 
analyser (Cobas INTEGRA 400 plus; Roche, Basel, 
Switzerland). Visual acuity was assessed at all clinic visits 
using a modified Snellen chart.29
Nitric oxide-dependent endothelial function was 
determined by FMD. FMD was assessed by one of two 
trained operators using high resolution ultrasound 
(Ultrasonix, Vancouver, Canada), in accordance with a 
standard protocol21 and verified by one of the 
investigators (EAE; appendix pp 5–6). Briefly, dilatation 
of the right brachial artery during reactive hyperaemia 
(maximal diameter change, % [FMDmax%]) was assessed 
after a 5-min cuff occlusion of the forearm. Changes in 
blood flow were also measured, and reactive hyperaemia 
was expressed as absolute change between baseline and 
peak velocity time integral (VTI). Endothelium-
independent responses to 5 µg sublingual glyceryl 
trinitrate were also assessed and expressed as percentage 
change in diameter.
Height and weight plus body composition (measured 
with a Tanita BC-418 Segmental Body Composition 
Analyser [Tanita, Tokyo, Japan]) were assessed by one of 
three trained clinical officers at each of the five clinic 
visits. Throughout the study, field workers administered 
short questionnaires on clinical complications, such as 
pain, when delivering the intervention at fortnightly 
home visits and by telephone in intervening weeks.
Outcomes
The primary outcome for a hypothesised effect of RUSF-v 
was mean differences between the RUSF-b and RUSF-v 
treatment groups in mean plasma aminoacid 
concentrations (arginine, arginine to ornithine ratio, and 
arginine to ADMA ratio) and in FMDmax%. This outcome 
was assessed in all patients at clinic visits 0, 1, and 3 for 
aminoacid concentrations and clinic visits 0, 1, 2, and 3 
for FMDmax%. The primary outcome for a hypothesised 
effect of both RUSF interventions combined was mean 
height and body-mass index (BMI) as Z-scores-for-age 
(by use of UK 1990 reference values in the zanthro 
program30 in Stata 14.1 [StataCorp, College Station, TX, 
USA]). This outcome was assessed at baseline and 
following both treatments and washouts in all patients.
The secondary outcomes were changes to mean 
haemoglobin concentration, haemolytic markers, 
C-reactive protein concentration, and number of reported 
painful episodes associated with RUSF treatments. 
Glomerular filtration rate was also a secondary outcome, 
but will be reported elsewhere. Visual acuity, serum liver 
and kidney function markers, and complete blood counts 
were safety monitoring outcomes.
Statistical analysis
A planned sample size of 120 was estimated to have more 
than 95% power to detect a potentially clinically im-
portant effect size of a change in FMDmax% of 1·25 units, 
equivalent to a 16% change in FMDmax% between RUSF-v 
and RUSF-b21,31 and a 20% difference in growth rates for 
height and weight in the RUSF intervention growth 
periods compared with the washout (appendix p 8).
Analysis was by intention to treat of the eligible study 
population and was done by use of Stata 14.1. Possible 
carry-over effects were assessed by non-paired t tests of the 
average of the observations after the two treatment periods 
(eg, average of value at time 1  plus value at time 3), and by 
treatment order (RUSF-v first or RUSF-v second;32 p values 
>0·1 accepted as no carry-over). The effect of RUSF-v 
compared with the effect of RUSF-b on outcomes within 
subjects, allowing for the presence of an order effect, was 
first assessed using non-paired t tests of the average 
difference between treatments (eg, average of values at 
time 3 [after the second treatment] minus values at 
time 1 [after the first treatment]) by the order in which 
RUSF-v was received.32 We then used mixed-effects general 
linear regression models, which account for repeated 
observations within individuals (measure ment occasion at 
level one; individuals at level two), to estimate the effects of 
each intervention compared with the baseline and washout 
values, and the effect of both treatments combined. Linear 
combination of effect estimates was used to estimate the 
effect of both RUSFs combined (ie, [β1 + β2]/2). Details of 
the models used are included in the appendix p 7–8. Due 
to several primary outcomes, p values <0·01 were taken as 
only indicative of a possible difference and values not 
reaching <0·001 were interpreted with caution. p values 
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between 0·001 and 0·01 were also interpreted with caution. 
No interim analyses were planned or done. The trial was 
overseen by a data safety monitoring committee. The trial 
is registered with ClinicalTrials.gov, number NCT01718054; 
and with ISRCTN74331412 (Jan 18, 2012).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Between July 16, 2012, and Aug 3, 2012, 166 potentially 
eligible children were identified from the Muhimbili 
Sickle Cohort database. No families refused to participate. 
Screening and enrolment were completed between 
Aug 9, 2012, and Dec 3, 2012. 145 children were 
determined to be clinically eligible during screening and 
A B
166 screened for eligibility
145 randomly assigned
21 did not meet inclusion criteria
7 out of age range
5 with inadequate visual acuity
2 taking hydroxyurea
3 with other illness
3 due to surpassing enrolment target
1 for several excluding factors
71 allocated to RUSF-v first
61 started RUSF-v first
60 attended first visit
59 attended third visit
58 attended fourth visit and 
completed the study*
60 attended second visit 
(and started RUSF-b)
 10 excluded for abnormal 
 liver and kidney 
 function
1 discontinued because 
of non-compliance
1 discontinued because 
of non-compliance
1 lost to follow-up
74 allocated to RUSF-b first
58 started RUSF-b first
58 attended first visit
58 attended third visit
57 attended fourth visit and 
completed the study
58 attended second visit 
(and started RUSF-v) 
16 excluded for abnormal 
 liver and kidney 
 function
1 died
First treatment
Mean duration 17 weeks (range 13–21)
Second treatment
Mean duration 16 weeks 
(range 15–19)
First washout
Mean duration 16 weeks (range 13–19)
Second washout
Mean duration 16 weeks 
(range 16–20)
9
3
2
28
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sit
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Figure 1: Trial profile
(A) Trial profile. (B) Timeline. RUSF=ready-to-use supplementary food. RUSF-v=vascular treatment. RUSF-b=basic food. *One participant had missing endothelial data.
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the baseline clinic visit (figure 1), and they were randomly 
assigned to treatment groups (71 children to RUSF-v first 
and 74 children to RUSF-b first). 26 children were later 
found to be ineligible because of abnormal kidney 
and liver function tests (as per the exclusion criteria; 
appendix p 1). 119 children were therefore initiated on the 
RUSF treatments (61 children in the RUSF-v first group 
and 58 children in the RUSF-b first group). 115 of these 
children completed the trial, attended all clinic visits, and 
had complete data (for aminoacid concen trations and 
Total (n=119) Male (n=71) Female (n=48)
Age
Age, years 10·01 (1·25) 10·14 (1·20) 9·81 (1·30)
Clinical observations
SpO2, % 98·97% (1·31) 98·82% (1·46) 99·21% (1·03)
Systolic blood pressure, mm Hg 102·82 (7·53) 103·55 (7·42) 101·75 (7·64)
Diastolic blood pressure, mm Hg 59·27 (7·58) 58·58 (7·09) 60·29 (8·21)
Palpable spleen, n (%) 18 (15%) 13 (18%) 5 (10%)
Jaundice, n (%) 
None 0 0 0
Mild 54 (45%) 31 (44%) 23 (48%)
Moderate 52 (44%) 31 (44%) 21 (44%)
Severe 13 (11%) 9 (13%) 4 (8%)
Blood markers
Haemoglobin, g/dL* 7·49 (1·09) 7·29 (1·07) 7·78 (1·07)
White cell count, × 10⁹ cells per L* 13·44 (3·43) 13·59 (3·53) 13·23 (3·31)
Platelet count, × 10⁹ cells per L* 449·55 (175·35) 452·64 (168·85) 445·10 (186·01)
Median C-reactive protein (IQR), mg/L 3·30 (1·60–6·60) 3·60 (1·60–7·00) 2·70 (1·55–6·30)
Median lactate dehydrogenase (IQR), U/L 597 (497–677) 585 (481–685) 607 (516–659)
Median total bilirubin (IQR), mg/dL 36·4 (25·6–47·9) 34·0 (24·8–46·6) 40·9 (29·7–54·4)
Median non-conjugated bilirubin (IQR), mg/dL 10·6 (8·3–13·2) 10·4 (8·0–11·9) 11·2 (9·0–13·5)
Median creatinine (IQR), μmol/L 22·0 (18·0–26·5) 22·8 (18·1–26·9) 21·4 (18·0–24·9)
Endothelial function
Flow-mediated dilatation, % 7·66% (3·37) 7·62% (3·54) 7·72% (3·12)
Resting brachial diameter, mm 2·61 (0·35) 2·67 (0·32) 2·52 (0·38)
Resting blood flow (VTI), m 0·20 (0·10) 0·20 (0·10) 0·20 (0·10)
Absolute reactive hyperaemia, m 0·69 (0·22) 0·72 (0·22) 0·66 (0·21)
Endothelium-independent vasodilatation
Response to glyceryl trinitrate, % 4·15% (1·72) 4·22% (1·74) 4·03% (1·69)
Aminoacid concentrations
Median arginine (IQR), μmol/L 54·40 (46·56–65·18) 55·62 (48·18–66·70) 51·79 (43·22–60·07)
Median citrulline (IQR), μmol/L 24·80 (21·28–28·50) 24·54 (20·58–29·08) 24·86 (21·62–28·23)
Median ornithine (IQR), μmol/L 52·80 (43·76–64·56) 51·78 (43·54–63·40) 55·55 (46·84–65·72)
Median arginine to ornithine ratio (IQR) 1·05 (0·88–1·28) 1·07 (0·94–1·34) 0·93 (0·74–1·15)
Median global arginine bioavailability ratio (IQR) 0·70 (0·58–0·84) 0·73 (0·62–0·88) 0·64 (0·53–0·76)
Median arginine to asymmetric dimethylarginine ratio (IQR) 53·27 (43·89–73·78) 55·37 (46·43–76·19) 51·15 (35·85–66·26)
Anthropometric measurements
Height, cm 126·5 (7·2) 126·9 (6·7) 125·9 (8·0)
Weight, kg 22·9 (3·6) 23·2 (3·2) 22·5 (4·0)
Fat-free body mass, kg 18·59 (2·77) 19·22 (2·49) 17·66 (2·94)
Body fat, % 18·76% (3·22) 17·03% (2·67) 21·30% (2·08)
Weight ≥25 kg, n (%) 33 (28%) 23 (32%) 10 (21%)
Height-for-age Z-score –2·09 (1·01) –2·14 (0·84) –2·01 (1·22)
Weight-for-age Z-score –2·58 (1·12) –2·65 (1·03) –2·48 (1·25)
Body-mass index Z-score –1·71 (0·88) –1·65 (0·86) –1·79 (0·90)
Data are mean (SD) unless otherwise indicated. VTI=velocity time intervals. SpO2=peripheral capillary oxygen saturation. *Total N is 117 because two full blood count results 
(from male patients) were lost before data entry.
Table 1: Baseline characteristics
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anthropometry), and 114 also had complete endothelial 
function data. Participants with bodyweights of less than 
25 kg and those with body weights of equal to or greater 
than 25 kg were evenly distributed between the two orders 
of treatment. At baseline (visit 0), 17 (28%) of 61 patients 
in the RUSF-v first group and 16 (28%) of 58 patients in 
the RUSF-b first group were at least 25 kg; at visit 3, the 
start of the second intervention, 31 (53%) of 59 patients in 
the RUSF-v first group and 26 (45%) of 58 patients in the 
RUSF-b first group were at least 25 kg.
Demographic, clinical, anthropometric, and laboratory 
values (including aminoacid concentrations) at baseline, 
both stratified by sex and combined, are reported in 
table 1. More boys (71 boys [60%] of 119 total patients) 
were recruited and were slightly older than girls. 
Variables that differed significantly by sex were 
haemoglobin concentration (higher in girls; p=0·017), 
fat-free body mass (lower in girls; p=0·002), and body fat 
percentage (greater in girls; p<0·0001); arginine to 
ornithine ratio (p=0·0076), global arginine bioavailability 
ratio (p=0·013), arginine to ADMA ratio (p=0·035), and 
resting brachial artery diameter (p=0·016) were also 
lower in girls than in boys. The proportion of girls 
weighing at least 25 kg at baseline (ten [21%] of 48), and 
therefore receiving the higher concentration of RUSF-v, 
was lower than in boys (23 [32%] of 71; p=0·17).
The mean compliance with RUSF (including coverage 
of supply and unused sachets) was 95%; 13 (11%) of 
119 participants had a mean compliance of less than 
90% and two (2%) of 119 had a compliance of less than 
80% (both of whom were discontinued). There was no 
difference in mean compliance between RUSF-v and 
RUSF-b treatment groups (p=0·47). Seven chloroquine 
syrup doses were reported to be consumed in the 
previous 7 days for 90% of doses, which did not 
significantly differ between the treatments (p=0·84).
Geometric means and 95% CIs of aminoacid 
concentrations at baseline (time 0), at the first washout, 
and after treatment (visit 1 or 3) are shown in table 2. The 
effects of the treatments, individually and combined, 
compared with baseline and washout measurements are 
shown in table 3, and adjusted effects are shown in the 
appendix (pp 11–12). In an analysis that was not 
prespecified, we compared the unadjusted effects of 
order of treatment by unpaired t tests (table 4). 
At baseline, there was no effect of age, sex, BMI Z-score, 
or weight category on aminoacid concentrations. There 
was no evidence of an order or carry-over effect of RUSF-v 
(arginine, p=0·35; ornithine, p=0·72; ADMA, p=0·96). 
The raw values of FMDmax%, brachial artery diameter at 
rest, blood flow at rest (as measured by VTI), absolute 
reactive hyperaemia, and response to glyceryl trinitrate at 
baseline by sex are shown in table 1. Means and 95% CIs 
of these measurements at baseline (time 0), after RUSF 
interventions (time 1 or 3), and at first washout (time 2) 
are shown in table 2. Baseline associations between these 
Baseline RUSF-v RUSF-b Washout 1
Aminoacid concentrations
Arginine, µmol/L 54·40 (51·71–57·22) 83·27 (75·13–92·29) 61·84 (58·57–65·29) ··
Citrulline, µmol/L 24·53 (23·41–25·70) 25·52 (22·91–28·41) 21·59 (20·68–22·53) ··
Ornithine, µmol/L 51·54 (47·85–55·52) 76·50 (69·61–84·08) 54·44 (51·59–57·44) ··
Asymmetric dimethylarginine, µmol/L 0·98 (0·91–1·06) 0·83 (0·79–0·88) 0·82 (0·76–0·88) ··
Arginine to ornithine ratio 1·06 (0·98–1·14) 1·09 (1·03–1·15) 1·14 (1·08–1·20) ··
Global arginine bioavailability ratio 0·70 (0·67–0·74) 0·81 (0·77–0·85) 0·80 (0·77–0·84) ··
Arginine to asymmetric dimethylarginine ratio 53·74 (49·54–58·29) 99·78 (89·93–110·70) 75·50 (69·19–82·38) ··
Endothelial function*
Flow-mediated dilatation, % 7·66% (7·04–8·27) 8·60% (7·97–9·23) 8·10% (7·53–8·66) 7·70% (7·11–8·29)
Brachial artery diameter at rest, mm 2·61 (2·55–2·67) 2·64 (2·58–2·71) 2·70 (2·63–2·78) 2·63 (2·56–2·70)
Baseline blood flow (VTI), m 0·20 (0·18–0·22) 0·22 (0·20–0·24) 0·24 (0·22–0·25) 0·19 (0·18–0·21)
Absolute reactive hyperaemia, m 0·69 (0·65–0·73) 0·77 (0·73–0·81) 0·78 (0·74–0·81) 0·78 (0·75–0·82)
Endothelium-independent vasodilatation* 
Response to glyceryl trinitrate, % 4·22% (3·81–4·64) 4·41% (4·04–4·78) 4·51% (4·10–4·92) 4·77% (4·43–5·11)
Blood markers
Haemoglobin, g/dL* 7·5 (7·3–7·7) 7·6 (7·4–7·8) 7·7 (7·6–7·9) 7·3 (7·1–7·4)
C-reactive protein, mg/L 3·35 (2·95–3·81) 3·84 (3·21–4·59) 3·94 (3·25–4·79) 3·51 (2·90–4·25)
Lactate dehydrogenase, IU/L 566 (548–585) 611 (576–649) 596 (561–633) 545 (519–573)
Total bilirubin, mg/dL 38·07 (35·44–40·89) 34·34 (30·00–39·32) 36·88 (32·80–41·48) 38·95 (34·93–43·43)
Non-conjugated bilirubin, mg/dL 27·03 (24·81–29·45) 24·53 (21·29–28·25) 24·93 (21·55–28·85) 27·94 (24·50–31·85)
Data are geometric mean (95% CI) and are natural log-transformed, unless otherwise indicated. RUSF=ready-to-use food supplement. v=vascular. b=basic.*Mean (95% CI).
Table 2: Concentrations of aminoacids, haemoglobin, C-reactive protein, and haemolytic markers and measures of endothelial and non-endothelial 
dependent vascular function before and after RUSF treatment
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measures and potential covariates are shown in the 
appendix (p 10). Values were similar at washout compared 
with baseline, with the exception of reactive hyperaemia, 
which had increased at the first washout. There was no 
evidence of an order effect or carry-over effect on 
FMDmax% (p=0·22).
When we assessed aminoacid concentration after each 
RUSF intervention compared with baseline (table 3), we 
found that, following RUSF-v treatment, there were 
significant increases to arginine, ornithine, the global 
arginine bioavailability ratio, and the arginine to ADMA 
ratio, and a decrease to ADMA (all p<0·0001). After RUSF-b 
treatment, there was an increase in arginine (p=0·008) and 
a significant increase to the global arginine bioavailability 
ratio and the arginine to ADMA ratio, and a significant 
decrease in ADMA (all p<0·0001). The global argin-
ine bioavailability ratio (arginine/ornithine + citrulline) 
increased to a similar extent after either treatment 
compared with baseline (15% increase; p<0·0001).
There was a greater decrease in ADMA after the 
RUSF-b intervention (18·9%) than after the RUSF-v 
intervention (9·5%; p<0·0001 for both treat ments), but 
this difference was not significant (table 3). There was a 
greater increase in the arginine to ADMA ratio after 
RUSF-v treatment (86%) than RUSF-b treatment (40%), 
but this difference was not significant (table 3). 
We found that, compared with RUSF-b, RUSF-v 
treatment significantly increased plasma arginine, 
ornithine, and the arginine to ADMA ratio and, to a 
lesser extent, citrulline. The increases to arginine and 
ornithine concentration were of similar magnitude 
within each group and, therefore, there was no difference 
to the arginine to ornithine ratio between RUSF-b and 
RUSF-v treatment groups.
RUSF-v RUSF-b RUSF combined
Coefficient (95% CI) p value Coefficient (95% CI) p value Coefficient (95% CI) p value
Aminoacids
Arginine, mmol/L 53·72 (39·09 to 68·20) <0·001 13·88 (3·05 to 24·60) 0·008 .. ..
Citrulline, mmol/L 4·08 (–4·87 to 13·88) 0·41 –11·93 (–19·84 to –3·29) 0·008 .. ..
Ornithine, mmol/L 47·69 (33·64 to 64·87) <0·001 5·13 (–4·87 to 17·35) 0·31 .. ..
Asymmetric dimethylarginine, mmol/L –9·51 (–24·42 to –4·877) <0·001 –18·94 (–25·91 to –11·30) <0·001 .. ..
Arginine to ornithine ratio 3·05 (–3·92 to 10·51) 0·40 7·25 (0 to 15·02) 0·04 .. ..
Global arginine bioavailability ratio 15·02 (9·42 to 20·92) <0·001 15·02 (8·33 to 20·92) <0·001 .. ..
Arginine to asymmetric 
dimethylarginine ratio 
85·89 (64·87 to 109·59) <0·001 40·49 (24·60 to 58·40) <0·001 .. ..
Endothelial function
Flow-mediated dilatation, %* 0·92 (0·30 to 1·54) 0·004 0·39 (–0·23 to 1·02) 0·22 0·66 (0·15 to 1·17) 0·011
Brachial artery diameter at rest, mm 0·03 (–0·01 to 0·07) 0·14 0·09 (0·05 to 0·13) <0·001 0·06 (0·03 to 0·09) <0·001
Baseline blood flow (VTI), m 0·024 (0·007 to 0·041) 0·007 0·043 (0·025 to 0·060) <0·001 0·033 (0·019 to 0·047) <0·001
Absolute reactive hyperaemia, m 0·03 (–0·01 to 0·07) 0·12 –0·04 (–0·01 to 0·08) 0·039 0·034 (0·004 to 0·065) 0·026
Endothelium-independent vasodilatation
Response to glyceryl trinitrate, % –0·04 (–0·44 to 0·37) 0·85 0·04 (–0·37 to 0·44) 0·86 0·00 (–0·33 to 0·33) 0·99
Blood markers
Haemoglobin, g/dL 0·23 (0·12 to 0·34) <0·001 0·35 (0·23 to 0·4) <0·001 0·29 (0·20 to 0·37) <0·001
C-reactive protein, mg/L 14·47 (–2·46 to 34·35) 0·098 17·39 (–0·09 to 37·94) 0·051 15·92 (1·684 to 32·15) 0·027
Lactate dehydrogenase, IU/L 7·70 (2·44 to 13·23) 0·004 5·10 (0·08 to 10·37) 0·046 6·39 (2·21 to 10·73) 0·002
Total bilirubin, mg/dL –12·20 (–19·72 to –3·98) 0·004 –4·0 (–12·25 to 5·02) 0·37 –8·19 (–14·66 to –1·23) 0·022
Non-conjugated bilirubin, mg/dL –11·25 (–19·38 to  –2·30) 0·015 –8·82 (–17·06 to 0·23) 0·056 –10·0 (–16·75 to –2·78) 0·007
Anthropometric measurements
Height-for-age Z-score .. .. .. .. 0·013 (–0·002 to 0·028) 0·081
Weight-for-age Z-score .. .. .. .. 0·070 (0·034 to 0·106) <0·001
Body-mass index-for-age Z-score .. .. .. .. 0·091 (0·039 to 0·143) 0·001
Fat-free body mass .. .. .. .. 0·14 (–0·25 to 0·31) 0·094
Body fat percentage .. .. .. .. 0·27 (0·04 to 0·49) 0·022
Estimates were assessed by use of natural log-transformed concentrations of aminoacids and blood component concentrations, except for haemoglobin; for these variables, 
estimates are the exponential and equivalent percentage change. RUSF=ready-to-use food supplement. *One extreme outlier value at baseline excluded. 
Table 3: Unadjusted estimates from multilevel models testing RUSF interventions compared with baseline and washout values (where available)
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When we assessed FMDmax% after each RUSF 
intervention compared with the baseline and washout 
timepoints (table 3), FMDmax% was increased following 
RUSF-v treatment (β coefficient 0·92; p=0·004). FMDmax% 
was also significantly increased (1·19; p<0·0001)  in the 
model adjusted for a priori covariates of age, sex, weight 
Median (IQR) or mean (SD) 
at time 1
Median (IQR) or mean 
(SD) at time 3
Mean within individual 
differences (SD)*
RUSF-v treatment effect 
(95% CI)*
p value*
Aminoacids
Arginine, μmol/L
RUSF-v first 74·84 (58·13–99·35) 57·66 (51·14–81·12) –30·80 (64·83) –60·01 (–82·17 to –37·85) <0·0001
RUSF-b first 58·25 (51·88–68·24) 77·17 (57·34–106·52) 29·21 (55·76) ·· ··
Citrulline, μmol/L
RUSF-v first 21·91 (18·10–28·69) 21·10 (18·82–25·18) –18·45 (67·47) –33·03 (–55·46 to –10·61) 0·0042
RUSF-b first 21·90 (19·08–25·48) 22·56 (19·48–27·70) 14·59 (54·12) ·· ··
Ornithine, μmol/L
RUSF-v first 64·80 (52·53–102·37) 49·38 (41·78–66·46) –48·50 (69·92) –72·13 (–94·74 to –49·53) 0·0001
RUSF-b first 53·68 (47·16–63·78) 68·81 (55·74–98·26) 23·64 (52·05) ·· ··
Asymmetric dimethylarginine, μmol/L
RUSF-v first 0·78 (0·67–0·98) 0·82 (0·68–1·06) 5·46 (57·89) –3·74 (–22·14 to 14·65) 0·6874
RUSF-b first 0·78 (0·66–0·88) 0·83 (0·72–0·96) 9·20 (40·99) ·· ··
Arginine to ornithine ratio
RUSF-v first 1·15 (0·96–1·33) 1·17 (1·01–1·48) 6·52 (26·92) 8·67 (–2·20 to 19·55) 0·12
RUSF-b first 1·05 (0·91–1·36) 1·10 (0·83–1·38) –2·15 (32·28) ·· ··
Global arginine bioavailability ratio
RUSF-v first 0·84 (0·73–0·97) 0·84 (0·75–1·02) 1·55 (23·12) –0·72 (–10·19 to 8·74) 0·88
RUSF-b first 0·76 (0·66–0·97) 0·78 (0·66–1·03) 2·28 (28·37) ·· ··
Arginine to asymmetric dimethylarginine ratio
RUSF-v first 97·53 (71·48–142·14) 78·64 (55·77–95·37) –36·26 (73·31) –56·26 (–81·38 to –31·13) <0·0001
RUSF-b first 75·58 (57·26–101·16) 94·49 (67·98–127·58) 20·00 (63·47) ·· ··
Endothelial function
Flow-mediated dilatation, %
RUSF-v first 8·20 (3·1) N=56 7·88 (3·20) N=56 –0·32 (4·02) –1·00 (–2·47 to 0·47) 0·1821
RUSF-b first 8·31 (2·91) N=58 8·98 (3·76) N=58 0·67 (3·93) ·· ··
Brachial artery diameter at rest, mm
RUSF-v first 2·66 (0·38) N=58 2·69 (0·42) N=58 0·03 (0·20) 0·10 (0·03 to 0·18) 0·0100
RUSF-b first 2·72 (0·39) N=58 2·64 (0·35) N=58 –0·08 (0·23) ·· ··
Baseline blood flow (VTI), m
RUSF-v first 0·24 (0·09) N=58 0·21 (0·08) N=58 –0·03 (0·10) 0·04 (0·00 to 0·07) 0·0460
RUSF-b first 0·27 (0·09) N=58 0·20 (0·09) N=58 –0·07 (0·10) ·· ··
Absolute reactive hyperaemia, m
RUSF-v first 0·76 (0·17) N=56 0·80 (0·21) N=56 0·04 (0·23) 0·03 (–0·06 to 0·11) 0·5454
RUSF-b first 0·75 (0·19) N=58 0·77 (0·23) N=58 0·02 (0·22) ·· ··
Response to glyceryl trinitrate, %
RUSF-v first 4·01 (1·71) N=56 4·62 (2·02) N=56 0·61 (2·52) 0·15 (–0·91 to 1·20) 0·7862
RUSF-b first 4·40 (2·41) N=57 4·86 (2·26) N=57 0·46 (3·12) ·· ··
Blood markers
Haemoglobin, g/dL
RUSF-v first 7·67 (1·04) N=59 7·55 (0 .96) N=59 –0·12 (0·64) 0·23 (–0·03 to 0·49) 0·0777
RUSF-b first 7·94 (1·01) N=58 7·58 (1·09) N=58 –0·36 (0·77) ·· ··
C-reactive protein, mg/L
RUSF-v first 2·90 (1·55–6·30) 3·60 (2·10–7·10) 118·91 (97·72) –14·77 (–57·51 to 27·96) 0·94
RUSF-b first 3·80 (1·80–8·20) 4·40 (1·80–8·50) 133·68 (107·48) ·· ··
Lactate dehydrogenase, IU/L
RUSF-v first 628 (500–730) 587 (479–705) 643·77 (33·13) 7·31 (–5·13 to 19·76) 0·51
RUSF-b first 589 (500–690) 617 (509–708) 636·46 (25·66) ·· ··
Table 4 continues on next page
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category, and other known important physiological 
determinants of the FMDmax% response (heart rate, 
brachial artery diameter before cuff inflation, reactive 
hyperaemia,34 and C-reactive protein as a measure of 
inflammatory status;35 appendix pp 11–12). FMDmax% was 
not increased following RUSF-b treatment, but there was 
an increase in the adjusted model (0·93, p=0·008). Neither 
treatment affected endothelium-independent vasodilator 
response to sublingual glyceryl trinitrate (table 3). 
FMDmax% did not appear to differ between the RUSF 
treatments; however, the combined estimate of the average 
effect of both RUSF interventions (compared with baseline 
and washout timepoints) showed an increase in FMDmax% 
of 0·66 (p=0·011; table 3) or 1·04 (p<0·0001) in the adjusted 
model (appendix p 11). Compared with RUSF-b there was 
no effect of RUSF-v on FMDmax% (table 4). 
Mean BMI-for-age Z-score, height-for-age Z-score, 
weight-for-age Z-score, fat-free body mass, and body fat 
percentage at each clinic visit are shown in figure 2. 
Following either RUSF intervention (compared with the 
baseline or after either washout), the combined estimate 
of the average effect of both treatments indicated 
significant but very small increases in weight-for-age 
Z-score and BMI-for-age Z-score (table 3). In a 
preplanned analysis model that was adjusted for age, sex, 
and seasonality, the effects of treatment increased slightly 
and were significant (p<0·0001; appendix pp 11–12).
Resting blood flow and reactive hyperaemia following 
treatment did not differ between the RUSF-b and RUSF-v 
interventions (table 4). The combined estimate of the 
average effect of both RUSF interventions (compared with 
the baseline and washout timepoints) showed a significant 
increase in VTI (0·0033 m; p<0·0001) and a non-
significant increase in reactive hyperaemia (0·0034 m; 
p=0·026; table 3).
Haemoglobin concentration was slightly but signifi-
cantly increased following the RUSF treatments 
(compared with the baseline and washout timepoints); the 
combined estimate for the average effect of both 
treatments was an increase of 0·29 g/dL (p<0·0001). 
C-reactive protein, lactate dehydrogenase, total and uncon-
jugated bilirubin concentrations did not differ after either 
RUSF intervention (table 3). However, in both treatments 
relative to baseline, we observed non-significant increases 
to lactate dehydrogenase and decreases to total and 
unconjugated bilirubin. In models adjusted for age, sex, 
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Figure 2: Anthropometry at each clinic visit
Data are mean ± 95% CI. At each timepoint: (A) height-for-age Z-scores; (B) weight-for-age Z-scores; (C) body-
mass index-for-age Z-scores; (D) body mass, stratified by sex; and (E) body fat, stratified by sex.
Median (IQR) at time 1 Median (IQR) at time 3 Mean within individual 
differences (SD)*
RUSF-v treatment effect 
(95% CI)*
p value*
(Continued from previous page)
Total bilirubin, mg/dL ··
RUSF-v first 35·85 (20·60–48·10) 39·60 (28·30–58·70) 359·44 (49·72) 10·88 (–11·68 to 33·46) 0·39
RUSF-b first 32·80 (22·20–44·50) 32·20 (26·20–56·10) 348·55 (58·63) ·· ··
Non-conjugated bilirubin, mg/dL
RUSF-v first 23·19 (11·50–34·70) 28·20 (16·90–46·80) 318·02 (61·46) 9·10 (–18·79 to 37·00) 0·84
RUSF-b first 21·30 (15·03–31·20) 20·55 (15·30–40·70) 308·92 (72·46) ·· ··
RUSF=ready-to-use food supplement. *Non-normally distributed variables were transformed for t tests with y=100*ln(x); for these, estimated effects can be interpreted as a 
percentage difference in treatment effect on the original scale,33 and a negative value indicates a positive RUSF-v treatment effect.
Table 4: Comparison of effects of RUSF-v and RUSF-b, showing mean within individual differences by treatment order
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and weight category, the combined estimate for the 
average effect of both interventions we also found a non-
significant decrease in non-conjugated bilirubin with both 
treatments (p=0·001; appendix pp 11–12). 
152 medical adverse events occurred in 83 participants, 
including 47 severe adverse events. Only 11 (7%) of 
152 adverse events were seen at Muhimbili National 
Hospital. The one death was associated with previous vaso-
occlusive pain and seizures in the second washout period. 
Similar numbers of adverse events occurred in the 
intervention (71 events; 21 events were serious) and 
washout periods (81 events; 26 events were serious; p=0·31; 
table 5). Vaso-occlusive coded adverse events were more 
frequent in intervention periods (29 events) compared with 
washout times (17 events; p=0·065), with no difference 
between treatments (table 5). There were no children with 
visual acuity less than 6/9 in either eye at any clinic visit.
Painful episodes (which were managed at home and 
recorded during weekly home visits or telephone calls) 
were also more frequent in the intervention periods 
(128 [5%] of 2555 assessments) compared with washout 
periods (92 [3%] of 3174 assessments; appendix p 13).
The number of adverse events related to laboratory 
findings at study visits increased after intervention 
periods compared with after the wash out periods: the 
number of tests out of normal clinical range for aspartate 
transaminase was 49 (21%) of 234 (intervention) 
compared with five (2%) of 233 (washout); for alkaline 
phosphatase, 11 (5%) of 234 tests were out of normal 
range (intervention) compared with 0 of 233 tests 
(washout); and, for total bilirubin, ten (5%) of 234 tests 
were out of normal clinical range (intervention) com-
pared with six (3%) of 233 tests (washout; appendix 
pp 13–14). However, these findings were mostly only of 
mild grade. Notably, there were fewer decreases in 
haemoglobin concentration after intervention periods 
(15 [6%] of 233 tests) than after washout (35 [15%] of 
233 tests). There was no indication of any differences 
Intervention (n=71) Washout (n=81) Total 
(n=152)
RUSF-v RUSF-b Total Washout 1 Washout 2 Total
Abscesses 0 0 0 1 moderate 0 1 1
Abdominal pain 0 1 moderate 1 2 moderate 0 2 3
Anaemia 0 0 0 1 moderate 0 1 1
Acid reflux 1 severe 0 1 0 0 0 1
Body weakness 0 0 0 1 mild 0 1 1
Chest tightness 1 severe 0 1 0 0 0 1
Chickenpox 1 moderate 0 1 1 moderate 0 1 2
Diarrhoea 1 moderate 0 1 0 3 moderate 3 4
Epigastric pain 0 0 0 1 severe 0 1 1
Fever with source 0 1 severe 1 1 mild 0 1 2
Fever without source 4 moderate 1 moderate 5 3 (2 moderate, 1 severe) 0 3 8
Headache 0 1 severe 1 0 0 0 1
Malaria 8 (1 mild, 2 moderate, 
5 severe)
10 (1 mild, 8 moderate, 
1 severe)
18 26 (2 mild, 16 moderate, 
8 severe)
11 (9 moderate, 
2 severe)
37 55
Measles 0 0 0 0 1 moderate 1 1
Muscle spasms 1 mild 0 1 0 0 0 1
Nosebleeds 0 1 moderate 1 0 0 0 1
Pulmonary tuberculosis 0 0 0 1 moderate 0 1 1
Stroke 1 moderate 0 1 0 0 0 1
Tonsilitis 2 moderate 0 2 1 mild 2 (1 moderate, 
1 severe)
3 5
Upper respiratory tract 
infections
2 moderate 4 (1 mild, 3 moderate) 6 3 (1 mild, 1 moderate, 
1 severe)
0 3 9
Urinary tract infections 0 0 0 3 (1 moderate, 2 severe) 1 mild 4 4
Vaso-occlusive pain 14 (2 mild, 5 moderate, 
7 severe)
15 (1 mild, 
10 moderate, 4 severe)
29 12 (1 mild, 3 moderate, 
7 severe, 1 very severe)
5 (1 mild, 
3 moderate, 
1 severe)
17 46
Vomiting 1 mild 0 1 0 0 0 1
Wounds 0 0 0 0 1 severe 1 1
Total 37 34 71 57 24 81 152
RUSF=ready-to-use food supplement.
Table 5: Causes and grade of adverse events by treatment periods
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between the RUSF treatments with regard to their effects 
on haemoglobin concentration (table 4).
Discussion
RUSF formulations, both with and without arginine and 
citrulline fortification and daily chloroquine, improve 
bioavailable arginine and might improve endothelium-
dependent vasodilator fun ction in Tanzanian children 
with sickle-cell disease.
Arginine and citrulline fortification and daily chloro-
quine in the RUSF-v intervention improved the 
concentration of bioavailable arginine (assessed by global 
arginine bioavailability ratio and arginine to ADMA 
ratio) and unexpectedly, the unfortified RUSF with 
weekly, low-dose chloroquine similarly increased global 
arginine bioavailability ratio and, to a lesser extent, the 
arginine to ADMA ratio in the patients. The effect of the 
RUSF-b intervention on the arginine to ADMA ratio 
appeared to be driven by a larger reduction in ADMA 
compared with baseline after RUSF-b treatment than 
after RUSF-v treatment, which, unsurprisingly, had a 
greater effect on arginine concentrations. Given evidence 
on the risk of cardiovascular outcomes in populations 
without sickle-cell disease, it seems likely that ADMA 
could be the most important determinant of vascular 
health.36 RUSF-v and RUSF-b groups did not significantly 
differ on measures of endothelial function. Effects of the 
RUSF interventions on anthropometric outcomes were 
significant but minimal. Both interventions appear safe, 
were well tolerated, and had good compliance.
The effect of oral L-arginine supplementation on 
vascular endpoints in sickle-cell disease adults is 
controversial. To our knowledge, this is the first trial of 
non-acute supplementation in children with sickle-cell 
disease. We found evidence to suggest a beneficial effect 
of both RUSF interventions on FMDmax%, with no effect 
on response to glyceryl trinitrate including in analyses 
adjusted for factors that might otherwise affect 
underlying vasomotor responses such as vessel size, 
heart rate, and inflammatory status. These findings 
suggest that this vascular effect is not a consequence of a 
change in smooth muscle function, but is more likely to 
be endothelium-dependent. Although this improvement 
was unexpected for RUSF-b, the larger reduction in 
ADMA following RUSF-b than following RUSF-v could 
underlie this effect, and suggests that additional protein 
might improve dysregulated arginine metabolism in 
sickle-cell anaemia.9 Additionally, although not 
significant, RUSF-b might have had a greater effect on 
resting blood flow (VTI), which could suggest improved 
resting microvascular dilator tone associated with this 
treatment. Furthermore, the increase in FMDmax% 
remained apparent after adjustment of relevant 
variables, including for reactive hyperaemia, suggesting 
that enhanced microvascular reactivity was also not 
responsible for the observed improvement in 
endothelium-dependent vasodilatation.
The effects of these interventions on BMI-for-age and 
height-for-age Z-scores were small, at least over this time 
period. Therefore, it would appear that the amount or 
duration of nutritional support, or both, were insufficient 
to greatly increase weight gain or to support linear growth. 
There was a marked drop in weight-for-age Z-scores and 
BMI-for-age Z-scores in the second washout period; body 
composition data suggested that this change was due to a 
decrease in fat mass while height-for-age Z-score 
increased. These findings suggest that resources were 
directed to linear growth in the second intervention at the 
cost of fat mass. An alternative interpretation would be an 
independent effect of season during the second washout 
period, although the fewer adverse events recorded in the 
second washout period makes this seem less likely.
Notably, there is only one published protein-energy 
supplementation study37 in sickle-cell disease, which 
investigated three children who were growth-retarded 
and were fed naso-gastrically (two children) or orally 
(one child); this study reported remarkable improvements 
in growth and clinical course in the two children fed 
naso-gastrically. Studies38 in transgenic mice for sickle-
cell disease show a higher protein requirement than 
control mice, with maximal growth and reduced end-
organ damage on a diet with 35% energy from protein. 
Increased protein, particularly increased arginine, also 
increased lean body mass, bone mineral density, and grip 
strength in these mice.39
We observed a significant small increase in haemo-
globin concentration after RUSF intervention, along with 
evidence of decreased concentrations of bilirubin 
markers of haemolysis but increased lactate dehydro-
genase relative to baseline and washout. In light of some 
increases in liver function tests after RUSF, this finding 
suggests that lactate dehydrogenase concentration might 
have increased due to effects on the liver. An absence of 
effect of RUSF-v containing daily chloroquine on 
C-reactive protein con centration does not support an 
anti-inflammatory effect of chloroquine, for which it has 
been used in conditions such as juvenile arthritis at 
similar doses.40
RUSF appears to be safe and well tolerated in 
Tanzanian children with sickle-cell disease, albeit with a 
possible increase in the frequency of pain-related adverse 
events and pain managed at home. This finding contrasts 
with evidence from a clinical trial19 of oral or intravenous 
arginine supplementation, which significantly reduced 
narcotic pain relief during acute painful episodes that 
required hospital treatment. However, there was quite a 
large difference in the number of adverse events between 
the first and second washout period; this difference could 
suggest an effect of seasonality, which is a limitation of 
crossover study designs and before-and-after intervention 
studies. This crossover trial in patients with limited 
access to emergency health care and imaging also 
limited the feasibility of assessing clinically important 
endpoints other than growth, pain, and haemoglobin 
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concentration. Although mortality is high in Tanzania,1 
only one child died in this relatively short study. Future 
studies of nutritional supplementation in other settings 
could report hospital admissions, (eg, for acute chest 
syndrome, CNS complications, or pain), outpatient 
prescriptions for analgesia, echocardiography or cardiac 
MRI for evidence of pulmonary hypertension or diastolic 
dysfunction, as well as brain MRI for volume or tissue 
characteristics as clinically relevant endpoints. Finally, 
we acknowledge that most of the significant observations 
of this study result from the analysis of the non-
randomised study design component with implications 
for the strength of evidence. However, this design 
allowed us to simultaneously assess effects on several 
endpoints in a smaller sample size with high power and 
to avoid the potential ethical issue of a placebo arm in a 
traditional parallel treatment arm trial.
This trial supports the use of protein energy 
supplementation in relatively malnourished children 
with sickle-cell disease to improve arginine availability, 
haemoglobin concentration and, possibly, vascular 
endothelial function. There were few additional benefits 
of an arginine and citrulline fortified so-called nutra-
ceutical RUSF compared with a basic RUSF. Larger trials 
of longer duration and, possibly, increased protein-
energy supply will be needed to determine the effects on 
endpoints of importance to patients, including growth, 
pubertal and cognitive development, hospital admissions, 
pain, vascular events, and exercise tolerance.
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